Original Source: DUKE-NUS MEDICAL SCHOOL
May 4, 2021 (DUKE-NUS Medical School) — Singapore scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients, and in uninfected individuals.
- Singapore study shows that SARS-CoV-2-specific T cells are present in all recovered COVID-19 patients.
- These T cells were also found in all subjects who recovered from SARS 17 years ago, and in over 50% of both SARS-CoV-1 and SARS-CoV-2 uninfected individuals tested, suggesting that a level of pre-existing SARS-CoV-2 immunity is present in the general population.
- Infection and exposure to coronaviruses induces long-lasting memory T cells, which could help in the management of the current pandemic.
The T cells, along with antibodies, are an integral part of the human immune response against viral infections due to their ability to directly target and kill infected cells. A Singapore study has uncovered the presence of virus-specific T cell immunity in people who recovered from COVID-19 and SARS, as well as some healthy study subjects who had never been infected by either virus.
The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore General Hospital (SGH) and National Centre for Infectious Diseases (NCID) was published in Nature. The findings suggest infection and exposure to coronaviruses induces long-lasting memory T cells, which could help in the management of the current pandemic and in vaccine development against COVID-19.
The team tested subjects who recovered from COVID-19 and found the presence of SARS-CoV-2-specific T cells in all of them, which suggests that T cells play an important role in this infection. Importantly, the team showed that patients who recovered from SARS 17 years ago after the 2003 outbreak, still possess virus-specific memory T cells and displayed cross-immunity to SARS-CoV-2.
“Our team also tested uninfected healthy individuals and found SARS-CoV-2-specific T cells in more than 50 percent of them. This could be due to cross-reactive immunity obtained from exposure to other coronaviruses, such as those causing the common cold, or presently unknown animal coronaviruses. It is important to understand if this could explain why some individuals are able to better control the infection,” said Professor Antonio Bertoletti, from Duke-NUS’ Emerging Infectious Diseases (EID) program, who is the corresponding author of this study.
Associate Professor Tan Yee Joo from the Department of Microbiology and Immunology at NUS Yong Loo Lin School of Medicine and Joint Senior Principal Investigator, Institute of Molecular and Cell Biology, A*STAR added, “We have also initiated follow-up studies on the COVID-19 recovered patients, to determine if their immunity as shown in their T cells persists over an extended period of time. This is very important for vaccine development and to answer the question about reinfection.”
“While there have been many studies about SARS-CoV-2, there is still a lot we don’t understand about the virus yet.”
“What we do know is that T cells play an important role in the immune response against viral infections and should be assessed for their role in combating SARS-CoV-2, which has affected many people worldwide.”
“Hopefully, our discovery will bring us a step closer to creating an effective vaccine,” said Associate Professor Jenny Low, Senior Consultant, Department of Infectious Diseases, SGH, and Duke-NUS’ EID program.
“NCID was heartened by the tremendous support we received from many previous SARS patients for this study. Their contributions, 17 years after they were originally infected, helped us understand mechanisms for lasting immunity to SARS-like viruses, and their implications for developing better vaccines against COVID-19 and related viruses,” said Dr Mark Chen I-Cheng, Head of the NCID Research Office.
The team will be conducting a larger study of exposed, uninfected subjects to examine whether T cells can protect against COVID-19 infection or alter the course of infection. They will also be exploring the potential therapeutic use of SARS-CoV-2-specific T cells.
Reference: “SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls” by Nina Le Bert, Anthony T. Tan, Kamini Kunasegaran, Christine Y. L. Tham, Morteza Hafezi, Adeline Chia, Melissa Hui Yen Chng, Meiyin Lin, Nicole Tan, Martin Linster, Wan Ni Chia, Mark I-Cheng Chen, Lin-Fa Wang, Eng Eong Ooi, Shirin Kalimuddin, Paul Anantharajal Tambyah, Jenny Guek-Hong Low, Yee-Joo Tan and Antonio Bertoletti, 15 July 2020, Nature. DOI: 10.1038/s41586-020-2550-z
Some of the movements I’m a huge fan of and hope you will learn more about…
None of the above listed companies/brands represent (a) relations of any kind and/or (b) endorsements and/or sponsorships of any kind. All trademarks and copyrights are the property of their respective owners.
VirtueAscends.com is working to become a certified 501c. We endeavor to publish content that educates, inspires, and compels audiences to search for the truth. All of it. Occasionally, our work will examine and address sensitive topics that may or may not be appropriate for all ages.
We will always work to keep our content accurate and whole. If you would like to learn more about citizen journalism efforts and/or would like to explore opportunities with us, please inquire via the About Us Section. Thank you for spending your time with us and we hope you will find our efforts worthy of your continued attention.